SAN - Banco Santander, S.A.

NYSE - NYSE Delayed Price. Currency in USD
4.6400
+0.1200 (+2.65%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close4.5200
Open4.6100
Bid4.61 x 301500
Ask0.00 x 36100
Day's Range4.5900 - 4.6600
52 Week Range4.2100 - 7.1000
Volume5,252,314
Avg. Volume7,769,855
Market Cap75.486B
Beta (3Y Monthly)0.75
PE Ratio (TTM)9.63
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.30 (6.60%)
Ex-Dividend Date2019-01-30
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire3 days ago

    Santander Consumer USA and Chrysler Capital each offer $10,000 grand prize in 'Go Paperless' campaign

    DALLAS, Feb. 12, 2019 /PRNewswire/ -- Santander Consumer USA ("SC") and Chrysler Capital are offering eligible1 customers who sign up for paperless statements as of April 1, 2019, the chance to win a $10,000 grand prize or one of five $500 prizes for each brand. When eligible1 Santander Consumer USA and Chrysler Capital customers enroll in e-statements at the appropriate website, they will be automatically entered into the sweepstakes. Eligible Santander Consumer USA and Chrysler Capital customers who already are enrolled in e-statements, also known as electronic or paperless statements, will be entered as well.

  • Santander Bank Promotes Robert Cerminaro to Commercial Banking Market Director for New England
    PR Newswire3 days ago

    Santander Bank Promotes Robert Cerminaro to Commercial Banking Market Director for New England

    BOSTON , Feb. 12, 2019 /PRNewswire/ -- Santander Bank today announced that Robert Cerminaro has been promoted to Commercial Banking market director for New England. He is responsible for managing and growing ...

  • GlobeNewswire4 days ago

    Sanofi appoints Ameet Nathwani Chief Digital Officer

    February 12, 2019 - Sanofi has appointed Ameet Nathwani, M.D. as Chief Digital Officer in addition to his current role of Executive Vice President, Chief Medical Officer. As Chief Digital Officer, Dr. Nathwani will be responsible for enhancing Sanofi's strategy to integrate digital technologies and medical science to ultimately improve patient outcomes.

  • GlobeNewswire9 days ago

    Sanofi delivers 2018 business EPS growth of 5.1% at CER

    Paris, February 7, 2019 Sanofi delivers 2018 business EPS growth of 5.1% at CER   Q4 2018 Change Change at CER  2018 Change Change at CER IFRS net sales.

  • GlobeNewswire9 days ago

    Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director

    February 6, 2019 - At its meeting held on February 6, 2019, the Board of Directors duly noted the resignation of Mr. Mulliez and decided, after consultation of the Appointments and Governance Committee, to co-opt Christophe Babule as Director for the remainder of Christian Mulliez's term of office (expiring at the end of the Annual Shareholders' Meeting held in 2022 to approve the financial statements for the fiscal year ending December 31, 2021). The co-optation of Christophe Babule will be subject to ratification by the next Shareholders' Meeting of Sanofi, on April 30, 2019. On November 19, 2018 Christophe Babule has been appointed Executive Vice-President, Chief Financial Officer and member of L'Oréal's Executive Committee as of mid-February 2019.

  • GlobeNewswire9 days ago

    Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

    February 6, 2019 - The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults.  Cablivi is the first FDA approved therapy specifically indicated for the treatment of aTTP.

  • GlobeNewswire11 days ago

    Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma

    Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma  Study evaluated the benefit.

  • GlobeNewswire12 days ago

    Sanofi: CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease

    February 4, 2019 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Praluent® (alirocumab), recommending a new indication as an adjunct to correction of other risk factors. Praluent should be used in addition to a maximally tolerated dose of statin or can be used alone in patients intolerant to or inappropriate for statin therapy. The CHMP opinion is based on data from ODYSSEY OUTCOMES, a Phase 3 cardiovascular outcomes trial that assessed the effect of Praluent in 18,924 patients who had an ACS between 1-12 months (median 2.6 months) before enrolling in the trial.

  • GlobeNewswire17 days ago

    Sanofi: Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo

    January 30, 2019 - Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis (HAT), more commonly known as sleeping sickness, has been granted in the Democratic Republic of Congo (DRC). This approval paves the way for the distribution of fexinidazole in endemic countries this year, with another submission planned in Uganda.

  • GlobeNewswire29 days ago

    Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes

    January 17, 2019 - The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) today voted eight to eight on the question of whether the overall benefits of Zynquista(TM)* (sotagliflozin) outweighed the risks to support approval. Sotagliflozin is an investigational oral dual SGLT1 and SGLT2 inhibitor under regulatory review as an adjunct to insulin for the treatment of adults with type 1 diabetes (T1D). While the FDA is not required to follow the committee's vote, the agency considers the committee's recommendations when making its decision, which is anticipated by March 22, 2019.

  • Santander Bank Continues to Enhance its Commercial Banking Capabilities with Specialized Banking Group
    PR Newswirelast month

    Santander Bank Continues to Enhance its Commercial Banking Capabilities with Specialized Banking Group

    BOSTON, Jan. 14, 2019 /PRNewswire/ -- Santander Bank today announced that its Commercial Banking division has enhanced its capabilities to better serve the needs of specific industries and has named Emily Vaughan Alexanderson to lead its specialized banking group, serving clients in the non-profit, educational, professional services, and technology and life sciences industries. David Harnisch, Santander Bank's Head of Commercial Banking, said, "We continue to make significant investments to support our growing commercial business and deliver valuable ideas to help our clients prosper.

  • Santander Bank Donates More than $2 Million to Non-Profit Organizations in Final Round of Funding in 2018
    PR Newswirelast month

    Santander Bank Donates More than $2 Million to Non-Profit Organizations in Final Round of Funding in 2018

    BOSTON , Jan. 14, 2019 /PRNewswire/ -- Santander Bank today announced that it has donated more than $2 million to 66 non-profit organizations that support low- and moderate-income (LMI) individuals, families ...

  • GlobeNewswirelast month

    Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs

    January 7, 2019 - Sanofi (EURONEXT: SAN, NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (REGN) have restructured their global Immuno-oncology Discovery and Development Agreement for new immuno-oncology cancer treatments. The 2015 Agreement was scheduled to end in approximately mid-2020, and this revision provides for ongoing collaborative development of two clinical-stage bispecific antibody programs.

  • Santander Bank Appoints Colleen Canny as Head of the Retail Network
    PR Newswire2 months ago

    Santander Bank Appoints Colleen Canny as Head of the Retail Network

    BOSTON, Dec. 20, 2018 /PRNewswire/ -- Santander Bank today announced the appointment of Colleen Canny as head of its Retail Network. Canny brings nearly 30 years of consumer banking and wealth management experience to Santander. Colleen is responsible for increasing colleague engagement and retention, deepening and growing customer relationships, and improving the customer experience to ensure the delivery of Santander's value proposition.

  • Santander Bank Raises Its Prime Rate to 5.50%
    PR Newswire2 months ago

    Santander Bank Raises Its Prime Rate to 5.50%

    BOSTON , Dec. 20, 2018 /PRNewswire/ -- Santander Bank announced today it has raised its prime rate from 5.25% to 5.50%, effective December 19, 2018 . Santander Bank , N.A .  is one of the country's largest ...

  • Santander Bank Opens Newest Branch in Brooklyn
    PR Newswire2 months ago

    Santander Bank Opens Newest Branch in Brooklyn

    BOSTON, Dec. 19, 2018 /PRNewswire/ -- Santander Bank today announced the opening of its newest branch in Brooklyn in the Bedford-Stuyvesant neighborhood, located on 1298 Fulton Street. To commemorate the new location, Santander leaders joined community partners at a grand opening celebration and ribbon cutting on Friday, Dec. 14 to officially open the branch. Santander presented checks totaling $26,000 to three community organizations – Brooklyn Neighborhood Services, Bedford Stuyvesant Restoration Corporation and New York Crusaders.

  • GlobeNewswire2 months ago

    Dengvaxia® vaccine approved for prevention of dengue in Europe

    December 19, 2018 - The European Commission has granted marketing authorization for Dengvaxia®, Sanofi's dengue vaccine. The marketing authorization follows the October 18, 2018, recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to approve use of the dengue vaccine in European endemic areas.

  • GlobeNewswire2 months ago

    Sanofi to Transfer U.S. Stock Exchange Listing to Nasdaq

    December 18, 2018 - Sanofi today announced that it will be transferring the listing of its American Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to The Nasdaq Global Select Market (Nasdaq) effective December 31, 2018, after market close. "This partnership with Nasdaq is a natural transition for Sanofi as it provides greater cost-efficiencies as well as access to a broad-based portfolio of investor relations tools to enhance both market insights and our interaction with the financial community," said Jean-Baptiste Chasseloup de Chatillon, Executive Vice President, Chief Financial Officer, Sanofi.

  • Santander Bank Names Seth Goodall Executive Director, Corporate Social Responsibility
    PR Newswire2 months ago

    Santander Bank Names Seth Goodall Executive Director, Corporate Social Responsibility

    BOSTON, Dec. 18, 2018 /PRNewswire/ -- Santander Bank today announced that it has named Seth Goodall as Executive Director, Corporate Social Responsibility. In this role, Goodall is responsible for overseeing Santander's activities related to the Community Reinvestment Act ("CRA") and general corporate stewardship for the communities where Santander operates.

  • Santander Bank Names David Harnisch Head of Commercial Banking
    PR Newswire2 months ago

    Santander Bank Names David Harnisch Head of Commercial Banking

    BOSTON, Dec. 3, 2018 /PRNewswire/ -- Santander Bank today announced that it has named David Harnisch Head of Commercial Banking. Harnisch joined Santander in 2017 as the Head of Underwriting, Portfolio Management and Commercial Strategy, and will now be responsible for leading and growing its commercial banking division.

  • PR Newswire3 months ago

    Santander Bank Opens First Branch in Flushing Neighborhood of Queens

    BOSTON, Nov. 5, 2018 /PRNewswire/ -- Santander Bank today announced the opening of its first branch in the Flushing neighborhood of Queens, located on 136-11 Roosevelt Avenue. To commemorate the event, Santander leaders will join community partners at a grand opening celebration and ribbon cutting later today to officially open the branch. Santander will present checks totaling $52,000 to three community organizations – Renaissance Economic Development Corporation (REDC), Chinese American Planning and Flushing Development Center.